Skip to main content
Erschienen in: Pathology & Oncology Research 2/2009

01.06.2009 | Original Paper

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

verfasst von: Sebastian Mannweiler, Peter Amersdorfer, Slave Trajanoski, Jonathan A. Terrett, David King, Gabor Mehes

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
Literatur
1.
2.
Zurück zum Zitat Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451PubMed Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451PubMed
3.
Zurück zum Zitat Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261CrossRefPubMed Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261CrossRefPubMed
4.
Zurück zum Zitat Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701CrossRefPubMed Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701CrossRefPubMed
5.
Zurück zum Zitat Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936PubMed Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936PubMed
6.
Zurück zum Zitat Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112PubMed Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112PubMed
7.
Zurück zum Zitat Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85PubMed Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85PubMed
8.
Zurück zum Zitat Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed
9.
Zurück zum Zitat Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334CrossRefPubMed Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334CrossRefPubMed
10.
Zurück zum Zitat Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197 Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197
11.
Zurück zum Zitat Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118CrossRefPubMed Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118CrossRefPubMed
12.
Zurück zum Zitat Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990) Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990)
13.
Zurück zum Zitat Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225CrossRefPubMed Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225CrossRefPubMed
14.
Zurück zum Zitat Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28CrossRefPubMed Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28CrossRefPubMed
15.
Zurück zum Zitat Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370CrossRefPubMed Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370CrossRefPubMed
16.
Zurück zum Zitat Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362PubMed Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362PubMed
17.
Zurück zum Zitat Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13CrossRef Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13CrossRef
18.
Zurück zum Zitat Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52CrossRef Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52CrossRef
Metadaten
Titel
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
verfasst von
Sebastian Mannweiler
Peter Amersdorfer
Slave Trajanoski
Jonathan A. Terrett
David King
Gabor Mehes
Publikationsdatum
01.06.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9104-2

Weitere Artikel der Ausgabe 2/2009

Pathology & Oncology Research 2/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.